Literature DB >> 17395448

Regulation of elastin promoter by lysyl oxidase and growth factors: cross control of lysyl oxidase on TGF-beta1 effects.

Roberta Oleggini1, Nicoletta Gastaldo, Armando Di Donato.   

Abstract

Lysyl oxidase (LOX) plays a key role in the maturation of the extra-cellular matrix, by inducing the formation of lysyl cross-links in collagen and elastin molecules. Beside its enzymic activity, LOX is able to regulate the promoter of collagen III, one of its natural substrates. In this paper we demonstrated that LOX regulates also the promoter of elastin, inducing an important activation of its activity. In order to define the pathways used by LOX to achieve its effect, we activated some of the main fibrogenic signal pathways and studied the consequences on LOX effects on the promoter. TGF-beta1 activated most of the elastin promoter constructs that we studied, except for an inhibitory region contained in the region between -1500 and -1000 bp. The treatment with TGF-beta1 abolished completely the activation induced by LOX. LOX-over-expression coupled with TGF treatment abolished both effects in the -500 bp region. The treatment with CTGF also inhibited LOX effect, although to a lesser extent. However, CTGF behaved quite differently from TGF-beta1 suggesting that it is not necessarily the mediator of TGF effects. Basic FGF, the other fibrogenic factor that we tested, again abolished LOX-dependent activation, but by itself did not affect elastin promoter activity. Because TGF-beta1 activating effects, we used EMSA to examine the transcription factor binding patterns in presence of LOX, TGF-beta1 or both. The study showed that LOX reverted the patterns of several DNA-protein complexes along the 1.5 kb of the studied promoter region. Most were affected by both LOX and TGF-beta1, while on some only TGF-beta1 was effective. LOX presence mostly inhibited the TGF-regulated complexes. Many of those included SMAD transcription factors. Two more restricted regions binding AP1 and SMAD were identified as mediators of LOX effects and of LOX and TGF-beta1 cross-inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17395448     DOI: 10.1016/j.matbio.2007.02.003

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  24 in total

1.  Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans.

Authors:  Vivian S Lee; Carmen M Halabi; Erin P Hoffman; Nikkola Carmichael; Ignaty Leshchiner; Christine G Lian; Andrew J Bierhals; Dana Vuzman; Robert P Mecham; Natasha Y Frank; Nathan O Stitziel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

Review 2.  Vascular extracellular matrix and arterial mechanics.

Authors:  Jessica E Wagenseil; Robert P Mecham
Journal:  Physiol Rev       Date:  2009-07       Impact factor: 37.312

3.  Controlling the fibroblastic differentiation of mesenchymal stem cells via the combination of fibrous scaffolds and connective tissue growth factor.

Authors:  Zhixiang Tong; Shilpa Sant; Ali Khademhosseini; Xinqiao Jia
Journal:  Tissue Eng Part A       Date:  2011-08-02       Impact factor: 3.845

4.  Engineered zinc-finger proteins can compensate genetic haploinsufficiency by transcriptional activation of the wild-type allele: application to Willams-Beuren syndrome and supravalvular aortic stenosis.

Authors:  Pei Zhang; Angela Huang; Manuel Morales-Ruiz; Barry C Starcher; Yan Huang; William C Sessa; Laura E Niklason; Frank J Giordano
Journal:  Hum Gene Ther       Date:  2012-11       Impact factor: 5.695

Review 5.  Molecular mechanisms of thoracic aortic dissection.

Authors:  Darrell Wu; Ying H Shen; Ludivine Russell; Joseph S Coselli; Scott A LeMaire
Journal:  J Surg Res       Date:  2013-06-29       Impact factor: 2.192

6.  Directed therapy for exfoliation syndrome.

Authors:  Allison Angelilli; Robert Ritch
Journal:  Open Ophthalmol J       Date:  2009-09-17

7.  Directed Therapy: An Approach to the Improved Treatment of Exfoliation syndrome.

Authors:  Allison Angelilli; Robert Ritch
Journal:  Middle East Afr J Ophthalmol       Date:  2009-01

8.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 9.  Genomic and proteomic pathophysiology of pseudoexfoliation glaucoma.

Authors:  Luis E Vazquez; Richard K Lee
Journal:  Int Ophthalmol Clin       Date:  2014

10.  VE-statin/egfl7 regulates vascular elastogenesis by interacting with lysyl oxidases.

Authors:  Etienne Lelièvre; Aleksander Hinek; Florea Lupu; Christelle Buquet; Fabrice Soncin; Virginie Mattot
Journal:  EMBO J       Date:  2008-05-22       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.